Source: Eur Respir Monogr 2012; 57: 1-16
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Tim Higenbottam. Pulmonary vascular disease: an historical perspective. Eur Respir Monogr 2012; 57: 1-16

Member's Comments

No comment yet.

Related content which might interest you: Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats Source: Eur Respir J 2011; 37: 813-822 Year: 2011 Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases Source: Eur Respir J 2008; 31: 343-348 Year: 2008 Transforming growth factor-β type II receptor in pulmonary arteries of patients with very severe COPD Source: Eur Respir J 2006; 28: 556-562 Year: 2006 Pathobiology of pulmonary arterial hypertension and right ventricular failure Source: Eur Respir J 2012; 40: 1555-1565 Year: 2012 Genetics of pulmonary hypertension: from bench to bedside Source: Eur Respir J 2002; 20: 741-749 Year: 2002 Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease Source: Eur Respir J 2009; 34: 1348-1356 Year: 2009 Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005 Pathobiology of pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 1559-1572 Year: 2002 Chronic thromboembolic pulmonary hypertension: role of medical therapy Source: Eur Respir J 2013; 41: 985-990 Year: 2013 Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy Source: Eur Respir Rev 2009; 18: 253-259 Year: 2009 Epoprostenol therapy for primary pulmonary hypertension after rejection of a single donor lung Source: Eur Respir J 2003; 21: 192-194 Year: 2003 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation Source: Eur Respir J 2003; 22: 560-562 Year: 2003 Pulmonary hypertension: future therapies Source: ISSN=1025-448x, ISBN=1-904097-31-6, page=84 Year: 2004 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension Source: Eur Respir J 2010; 36: 1302-1314 Year: 2010 Is sildenafil an effective bridging therapy to lung transplantation for patients with pulmonary hypertension in the setting of lung disease? Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Effects of erythropoietin on advanced pulmonary vascular remodelling Source: Eur Respir J 2008; 31: 126-134 Year: 2008 Long-term outcome with intravenous iloprost in pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 132-137 Year: 2009